MUMBAI, India, Oct. 31 -- Intellectual Property India has published a patent application (202547095117 A) filed by Akeso Biopharma Co. Ltd., Guangdong, China, on Oct. 3, for 'anti-lag3 antibody, pharmaceutical composition, and use.'
Inventor(s) include Li, Baiyong; and Xia, Yu.
The application for the patent was published on Oct. 31, under issue no. 44/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to an anti-LAG3 antibody, a pharmaceutical composition, and a use. Specifically, the present invention relates to an anti-LAG3 antibody or an antigen-binding fragment thereof. The anti-LAG3 antibody comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The amino acid sequence of HCDR1 is as shown in SEQ ID NO: 9, the amino acid sequence of HCDR2 is as shown SEQ ID NO: 10, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO: 11. The amino acid sequence of LCDR1 is as shown in SEQ ID NO: 12 or SEQ ID NO: 17, the amino acid sequence of LCDR2 is as shown in SEQ ID NO: 13 or SEQ ID NO: 15, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO: 14 or SEQ ID NO: 16. The anti-LAG3 antibody has excellent affinity and specificity, and has good prospects for anti-tumor application."
The patent application was internationally filed on Mar. 28, 2024, under International application No.PCT/CN2024/084453.
Disclaimer: Curated by HT Syndication.
